Yusuke Nakamura to Antineoplastic Agents
This is a "connection" page, showing publications Yusuke Nakamura has written about Antineoplastic Agents.
Connection Strength
2.954
-
Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor. Oncotarget. 2016 Apr 05; 7(14):18171-82.
Score: 0.249
-
Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Sci. 2016 Feb; 107(2):107-15.
Score: 0.246
-
Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug; 104(8):1074-82.
Score: 0.205
-
A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients. Breast Cancer Res. 2013; 15(5):R81.
Score: 0.199
-
Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. Int J Oncol. 2009 Feb; 34(2):361-70.
Score: 0.152
-
Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008 May; 99(5):967-72.
Score: 0.142
-
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 2004 Dec 15; 13(24):3029-43.
Score: 0.113
-
Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839. Int J Oncol. 2003 Jul; 23(1):29-39.
Score: 0.103
-
Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene. 2003 Apr 10; 22(14):2192-205.
Score: 0.101
-
[SNP collection, pharmacogenomics, and the future of drug therapy]. Gan To Kagaku Ryoho. 2002 Sep; 29(9):1665-73.
Score: 0.097
-
Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 2002 Jan 15; 62(2):518-27.
Score: 0.093
-
Functional genomics for breast cancer drug target discovery. J Hum Genet. 2021 Sep; 66(9):927-935.
Score: 0.090
-
Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia. J Immunol. 2018 10 01; 201(7):1967-1974.
Score: 0.073
-
WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer. Sci Rep. 2017 01 19; 7:40664.
Score: 0.066
-
Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells. Blood Cancer J. 2016 08 19; 6(8):e460.
Score: 0.064
-
Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. Oncotarget. 2016 Mar 22; 7(12):13621-33.
Score: 0.062
-
Dysregulation of protein methyltransferases in human cancer: An emerging target class for anticancer therapy. Cancer Sci. 2016 Apr; 107(4):377-84.
Score: 0.062
-
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget. 2015 Oct 20; 6(32):33410-25.
Score: 0.060
-
Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity. J Med Chem. 2015 Feb 26; 58(4):1760-75.
Score: 0.058
-
TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med. 2014 Oct 22; 6(259):259ra145.
Score: 0.056
-
Downregulation of the tumor suppressor HSPB7, involved in the p53 pathway, in renal cell carcinoma by hypermethylation. Int J Oncol. 2014 May; 44(5):1490-8.
Score: 0.054
-
Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells. Nat Commun. 2013; 4:2443.
Score: 0.050
-
Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012 Dec; 3(12):1629-40.
Score: 0.049
-
Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data. Pharmacogenomics. 2011 Jul; 12(7):965-75.
Score: 0.045
-
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol. 2010 Nov 01; 28(31):4674-82.
Score: 0.042
-
[S-1/CDDP combined neoadjuvant chemotherapy and surgical resection for advanced gastric cancer. Analysis of 12 patients with lymph node metastasis in Saitama Red Cross Hospital]. Gan To Kagaku Ryoho. 2009 Aug; 36(8):1287-91.
Score: 0.039
-
From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg. 2008 Feb; 56(2):43-53.
Score: 0.036
-
The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res. 2006 Oct 01; 66(19):9408-19.
Score: 0.032
-
Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol. 2006 Sep; 29(3):567-75.
Score: 0.032
-
Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target. Int J Oncol. 2006 Aug; 29(2):381-6.
Score: 0.032
-
Molecular target therapy for synovial sarcoma. Future Oncol. 2005 Dec; 1(6):805-12.
Score: 0.030
-
Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res. 2005 Oct 15; 65(20):9176-84.
Score: 0.030
-
Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol. 2004 Mar; 24(3):647-55.
Score: 0.027
-
Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis. Mol Cell Biol. 2002 Dec; 22(24):8695-708.
Score: 0.025
-
Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. Jpn J Cancer Res. 2002 Aug; 93(8):849-56.
Score: 0.024
-
An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 2002 Feb 15; 62(4):1139-47.
Score: 0.023
-
Genome-wide screening by cDNA microarray of genes associated with matrix mineralization by human mesenchymal stem cells in vitro. Biochem Biophys Res Commun. 2002 Jan 11; 290(1):381-90.
Score: 0.023
-
The NSD family of protein methyltransferases in human cancer. Epigenomics. 2015 Aug; 7(5):863-74.
Score: 0.015
-
In vivo therapeutic effect of CDH3/P-cadherin-targeting radioimmunotherapy. Cancer Immunol Immunother. 2012 Aug; 61(8):1211-20.
Score: 0.012
-
Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 2009 Aug 15; 69(16):6694-703.
Score: 0.010
-
[A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer]. Gan To Kagaku Ryoho. 2008 Nov; 35(12):2271-3.
Score: 0.009
-
Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6624-31.
Score: 0.009
-
Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Int J Oncol. 2007 Aug; 31(2):313-22.
Score: 0.009
-
Identification of candidate predictive markers of anticancer drug sensitivity using a panel of human cancer cell lines. Cancer Sci. 2003 Dec; 94(12):1074-82.
Score: 0.007